Resumen
The discovery of prognostic biomarkers constitutes an important issue because it allows the tailoring of therapeutic treatments, thus avoiding over-treatment and side effects. In this context, reliable prognostic biomarkers advance the field of precision oncology. Such biomarkers are usually discovered in the tumor tissue, which is not an easy task given the inaccessibility of malignant tissue in many types of cancer. In this work, we could identify a prognostic signature consisting of eight genes for prostate cancer patients. This biosignature was identified in peripheral blood samples, which are easy to access and, importantly, have a significant prognostic value for various types of cancer.